Figure 6.
RvE1 and LXA4 utilize distinct mechanisms to promote resolution of airway inflammation. a, Total BALF leukocytes from mice given RvE1, ATLa or RvE1 plus ATLa. b-d, Concentrations of IL-17, IL-23 and IFN-γ in BALF were measured by cytokine bead array. e, The inhibitory effect of increasing concentrations of RvE1 on IL-23 release from LPS-stimulated BMDCs was measured as a percentage of maximum (89.5 pg/ml/million cells). The LXA4 receptor antagonist BOC-2 (10 μM) was added where indicated. Results are expressed as mean ± s.e.m. *, P < 0.05. f, Concentrations of IL-6 and TNF released from LPS-activated BMDCs treated with vehicle or 1ng/ml RvE1 were measured by cytokine bead array. Results are expressed as mean ± s.e.m for n ≥ 3 in ≥ 2 independent experiments. *, P < 0.05 by one-way ANOVA.